Caris

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

Retrieved on: 
Monday, January 8, 2024

SINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.

Key Points: 
  • SINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.
  • Now in its seventh year, Acquisition International's M&A Awards recognizes the excellence of top executives, analysts, investors, and professionals in the M&A sector across diverse industries.
  • In the healthcare domain, Juniper Biologics stands out for the second consecutive year, this time for its acquisition of Caris Molecular Intelligence®, a tumour profiling service for Asia.
  • On being awarded the M&A Awards for the Molecular Science & Technology Acquisition of the Year, Raman Singh, CEO of Juniper Biologics expressed: "We're deeply honored to receive recognition once again, this time for the acquisition of Caris Molecular Intelligence®.

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

Retrieved on: 
Monday, January 8, 2024

SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.

Key Points: 
  • SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.
  • Now in its seventh year, Acquisition International's M&A Awards recognizes the excellence of top executives, analysts, investors, and professionals in the M&A sector across diverse industries.
  • In the healthcare domain, Juniper Biologics stands out for the second consecutive year, this time for its acquisition of Caris Molecular Intelligence®, a tumour profiling service for Asia.
  • On being awarded the M&A Awards for the Molecular Science & Technology Acquisition of the Year, Raman Singh, CEO of Juniper Biologics expressed: "We're deeply honored to receive recognition once again, this time for the acquisition of Caris Molecular Intelligence®.

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 4, 2023

IRVING, Texas, Dec. 4, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment. SABCS is being held December 5-9, 2023 (Booth #1433) in San Antonio, Texas.

Key Points: 
  • "The San Antonio Breast Cancer Symposium continues to be the premiere conference for breast cancer research," said George W. Sledge, Jr. , MD, Executive Vice President and Chief Medical Officer of Caris.
  • "As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical/translational research created with our academic partners on important breast cancer questions."
  • The results of this analysis indicate that male breast cancer has differential molecular and immune features compared to female breast cancer.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Rob Clark Joins FGS Global as Senior Executive

Retrieved on: 
Monday, March 27, 2023

FGS Global, the strategic advisor for the stakeholder economy, today announced that Rob Clark has joined the company as a Managing Director based in Chicago.

Key Points: 
  • FGS Global, the strategic advisor for the stakeholder economy, today announced that Rob Clark has joined the company as a Managing Director based in Chicago.
  • Clark brings more than 25 years of communications and government affairs leadership experience spanning the healthcare, telecommunications, and energy sectors.
  • He most recently served as Senior Vice President and Chief Marketing & Communications Officer for Caris Life Sciences.
  • At FGS Global, he will counsel clients on a range of matters including corporate communication, activism, M&A, and ESG.

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022

Key Points: 
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $613.5 million as of December 31, 2022, compared to $664.1 million on December 31, 2021.
  • Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.
  • General and administrative (G&A) expenses for the fourth quarter ended December 31, 2022 were $12.8 million compared to $11.4 million for the same period in 2021.
  • ET (1:30 p.m. PT) to discuss the full year 2022 financial results and provide a corporate update.

ConcertAI Presentation at JP Morgan Healthcare Conference Outlines Key Advances in DaaS and AI SaaS Research Platforms for Translational Sciences and Clinical Development

Retrieved on: 
Tuesday, January 10, 2023

CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.
  • In late 2022, ConcertAI and Caris Life Sciences launched a broadscale reference platform for Translational Sciences, announced publicly on January 9, 2023.
  • The collaboration creates the leading and most comprehensive oncology translational and clinical development multi-modal research data platform aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.
  • This leadership teams' experience and depth of expertise in research, services, and oncology technologies is unprecedented in the industry."

Day Zero Diagnostics Welcomes Healthcare Business Leader Gail Marcus to its Board

Retrieved on: 
Wednesday, November 9, 2022

"We are pleased to welcome Gail Marcus to the Day Zero Diagnostics Board of Directors.

Key Points: 
  • "We are pleased to welcome Gail Marcus to the Day Zero Diagnostics Board of Directors.
  • "I'm excited to work with the Day Zero Diagnostics executive team and board as the company continues to advance its disruptive approach to infectious disease diagnosis, with the mission to help curb the growing global healthcare crisis of antibiotic resistance," said Gail Marcus.
  • Day Zero Diagnostics most recently announced an additional $8.2 million in non-dilutive funding from CARB-X for the development of its sequencing based diagnostic system.
  • Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital.

Labroots Announces Full Three-Day Agenda for its 10th Annual Cancer Research & Immuno-Oncology Week Event, Held on October 4-6, 2022

Retrieved on: 
Wednesday, September 21, 2022

YORBA LINDA, Calif., Sept. 21, 2022 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its 10th annual Cancer Research and Immuno-Oncology Week conference on October 4-6, 2022. The three-day content-rich agenda continues to be the go-to-meeting sharing cutting-edge discoveries and novel advancements via invited lectures and thought-provoking discussions to improve the outcomes and treatments of patients with cancer.

Key Points: 
  • Cancer Research & Immuno-Oncology Week offers a prestigious forum for some of the brightest minds in the field to collaborate and share knowledge in emerging topics including cancer research, novel targeted therapies in cancer, immuno-oncology, cell therapy, and cancer research networks, epidemiology and patient advocacy.
  • Use the hashtag #LRcancer to follow the conversation and connect with members of the global Cancer & Oncology Research community!
  • Follow @Cancer_LR on Twitter and @CancerResearchandOncology.LR on Facebook to connect with our specialist Cancer & Oncology writers and stay up to date with the latest news in Cancer & Oncology Research.
  • Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities.